ClinicalTrials.gg
CompletedNCT02076659Updated May 18, 2018

Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients

A Phase 1 interventional study of F8IL10 and Methotrexate in Rheumatoid Arthritis, sponsored by Philogen S.p.A.. Completed at 5 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-05-18.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Sep 2011, registered Feb 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
96th of 113
36 · median 130
Started
2011
with 6 others
Phase 1
12 of 113
none open now
Registered
80th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 96th largest by enrollment, is one of 7 that started in 2011, is one of 12 in phase 1, and was the 80th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.

Read the detailed description

The study is designed to explore whether F8IL10 can be safely administered in combination with standard-dose of MTX in patients with active rheumatoid arthritis and to determine the recommended dose of F8IL10 when combined with MTX.

As soon as the MTD/RD is determined, an additional 12 patients will be randomized (6+6) between F8IL10 (RD) and placebo to further investigate the safety and pharmacacodynamics profile of the study treatment.

Methotrexate (MTX) will be administered as concomitant medication in the dose escalation as well as in the randomized part of the study.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • F8
  • IL10
  • Interleukin
  • monoclonal
  • antibody
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 18 and \< 75 years.
  2. Diagnosis of RA according to ACR criteria (1987) with a disease duration exceeding 12 months.
  3. Active RA (DAS28 ≥ 3.2) for ≥ 4 months at time of signing .
  4. Receiving treatment on an outpatient basis.
  5. MTX at 10-15 mg/w for a period ≥ 8 weeks prior to treatment.
  6. Inadequate clinical response to at least one anti-TNF therapy applied for at least 4 months.
  7. If patients are receiving an oral , the dose must have been stable for at least 25 out of 28 days prior to study treatment and the dose must be less than 10 mg/day (prednisolone equivalent).
  8. All acute toxic effects of any prior therapy must have returned to classification "mild" according to RCTC V.2.0 [1] .
  9. Sufficient hematologic, liver and renal function:

    • (ANC) ≥ 1.5 x 109/L, ≥ 100 x 109/L, (Hb) ≥ 9.5 g/dL
    • Alkaline phosphatase (AP), (ALT) and or aspartate aminotransferase (AST) ≤ 3 x (ULN), and total ≤ 2.0 mg/dL (34.2 µmol/L)
    • Creatinine ≤ 1.5 ULN or 24 h ≥ 50 mL/min
  10. Documented negative test for , , and . For patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV DNA is required.
  11. Male and female patients, who are potentially fertile, must agree to use adequate methods at the beginning of the screening visit that must be continued until 3 months following the last treatment with study drug.
  12. Negative serum pregnancy test (for women of only) at screening.
  13. Signed and dated Ethics Committee-approved Informed Consent Form indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the study.
  14. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion criteria

  1. Presence of active infections (e.g. requiring antibiotic therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or would interfere with the study objectives or conduct.
  2. Pregnancy, lactation or unwillingness to use adequate methods.
  3. Active or latent tuberculosis (TB).
  4. Chronic active hepatitis or active diseases other than RA.
  5. History of currently active primary or secondary immounodeficiency.
  6. Infection.
  7. Acute or chronic-active infection with or , as assessed by serology or HBV DNA.
  8. Evidence of active malignant disease at screening or advanced diagnosed within the previous 5 years.
  9. Any previous treatment with alkylating agents, such as cyclophosphamide or chlorambucil or with total lymphoid irradiation.
  10. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  11. Treatment with warfarin or other coumarin derivatives.
  12. Heart insufficiency (> Grade II, (NYHA) criteria).
  13. Irreversible cardiac arrhythmias requiring permanent medication.
  14. (to clinical investigator's discretion) abnormalities in baseline , ECHO or analyses.
  15. Uncontrolled hypertension.
  16. Ischemic peripheral vascular disease (Grade IIb-IV).
  17. Severe diabetic retinopathy.
  18. Major trauma including surgery within 4 weeks of administration of study treatment.
  19. Known history of allergy or other intolerance to IL10, MTX, folic acid or other drugs based on human proteins/peptides/antibodies.
  20. In vivo exposure to monoclonal antibodies for biological therapy (e.g., adalimumab,infliximab golimumab, tocilizumab, certolizumab pegol) less than 8 weeks prior to administration of study medication.
  21. Treatment with rituximab less than 4 months prior to administration of study medication.
  22. Treatment with fusion proteins (e.g. abatacept, etanercept) less than 4 weeks prior to administration of study medication.
  23. Treatment with any agent within the 6 weeks before study treatment.
  24. Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.
  25. Growth factors or immunomodulatory agents, including anakinra, within 7 days of the administration of study treatment.
  26. Neuropathy > Grade 1 or Neuropathies or other painful conditions (not RA-related) that might interfere with pain evaluation.
  27. Patients required to be treated with at a dose > 10 mg/day or with drugs other than MTX on a long-term basis. Limited use of corticosteroids to treat or prevent acute reactions is not considered an exclusion criterion.
  28. History of alcohol, drug or chemical substance abuse within the 6 months prior to screening.
  29. Body weight of >100 kg.
  30. Any condition that in the opinion of the investigator could hamper compliance with the study protocol.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    F8IL10 + MTX

    Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid. An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication. In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2.

    Drug: F8IL10 · Drug: Methotrexate

Interventions

  • DrugF8IL10

    Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study. F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.

  • Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.). Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events that are related to treatment and classified as DLTs for each administered dosage

    To establish the MTD and the RD of F8IL10 when administered in combination with methotrexate

    Time frame: Up to day 28

Secondary outcomes

  1. Maximum drug concentration [Cmax]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  2. Time to reach maximum drug concentration [Tmax]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  3. Terminal half-life [t1/2]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  4. Area under the drug concentration-time curve [AUC(0 - t last)]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  5. Area under the drug concentration-time curve, extrapolated to infinity [AUC]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  6. Accumulation ratio for AUC [R AUC]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  7. Accumulation ratio for Cmax [Rmax]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  8. Accumulation ratio for Cmin [R min]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  9. Total clearance following the dose administered [CL]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  10. Volume of distribution at steady state [Vss]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  11. Mean residence time [MRT]

    Pharmacokinetics assessment of F8IL10 through blood sampling

    Time frame: At day 1, 4, 5, 6 of week 1; at day 1, 2, 3, 4, 5, 6 of week 4

  12. Human anti-fusion protein antibodies (HAFA) levels

    Investigate the potential induction of human anti-fusion protein antibodies (HAFA) through standard laboratory analysis.

    Time frame: 1) at day 1 of week 1; 2) at day 1 of week 4; 3) from week 5 up to week 9 (EoT visit)

  13. Response rate according to EULAR criteria (Good, Moderate and Non-responders) based on DAS28 score

    To explore the antiarthritic activity of the study medication in patients with active rheumatoid arthritis.

    Time frame: 1) from day -14 up to day 0 (screening); 2) at day 1 of week 5; 3) at day 1 of week 9; 4) from week 9-13 up to week 57-61, every 4 weeks (safety/efficacy follow-up)

  14. ACR 20, ACR 50, ACR 70 response rate

    To explore the antiarthritic activity of the study medication in patients with active rheumatoid arthritis.

    Time frame: 1) from day -14 up to day 0 (screening); 2) at day 1 of week 5; 3) at day 1 of week 9; 4) from week 9-13 up to week 57-61, every 4 weeks (safety/efficacy follow-up)

  15. Change from baseline in DAS28

    To explore the antiarthritic activity of the study medication in patients with active rheumatoid arthritis.

    Time frame: 1) from day -14 up to day 0 (screening); 2) at day 1 of week 5; 3) at day 1 of week 9; 4) from week 9-13 up to week 57-61, every 4 weeks (safety/efficacy follow-up)

  16. Relative change over time of blood biomarkers

    Time frame: From day -14 up to day 0 (screening); at day 1 of week 1; at day 1 of week 5 /week 9 (EoT); from week 7 up to week 11 (safety follow-up); from week 11 up to week 15 (efficacy follow-up); from week 11-15 up to week 57-61, every 4 weeks (total follow-up)

07

Study locations

5 sites
  • Policlinico San Matteo, Pavia
    Pavia, Italy
  • Pisa University Hospital
    Pisa, Italy
  • Azienda Ospedaliera San Camillo-Forlanini Roma
    Roma, Italy
  • Policlinico A. Gemelli, Università Cattolica del Sacro Cuore
    Roma, Italy
  • Siena University Hospital
    Siena, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Apr 2017, 67 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 67 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2014
First posted
Mar 3, 2014
StartActual
Sep 2011
Primary completionActual
Apr 2017
CompletionActual
Apr 13, 2017
Last update
May 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02076659
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Sep 2011
Primary completion
Apr 2017
Completion
Apr 13, 2017
Last update
May 18, 2018

Study contacts

Mauro Galeazzi, Prof
principal investigator · Siena University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion